|
|
|
 16/02/2010
[Industry news]
Skystar Bio-Pharmaceutical (CGPN) Included in New York Pacific Capital China SME Growth Index
Skystar Bio-Pharmaceutical Company, a China-based producer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, today announced the Company\'s inclusion in the New York Pacific Capital (NYPC) China Small and Medium Enterprises (SME) Growth Index.
|
| |
|
Skystar Bio-Pharmaceutical Company, a China-based producer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, today announced the Company\'s inclusion in the New York Pacific Capital (NYPC) China Small and Medium Enterprises (SME) Growth Index.
The index, which launched on January 1, 2010, is currently composed of 58 Chinese companies with market capitalizations ranging from $50 million to $1.5 billion. The index is designed to measure and monitor the performance of high-growth small- and mid-cap Chinese companies traded on exchanges outside of mainland China. The 58 companies included at launch were selected from 319 companies listed on exchanges in the United States, Hong Kong, Canada, Europe, Singapore, Japan and Korea. The companies that were initially included had revenue growth rates at least double the China GDP growth rate along with positive net margin, daily trading value over $500,000, and a minimum public float of 30% of the total outstanding shares.
\"We are very pleased to be included in this index,\" said Weibing Lu, Skystar\'s Chairman and Chief Executive Officer. \"We believe Skystar\'s inclusion in the index will assist in gaining further investor awareness among China-focused investors worldwide.\" |
|
|
|
|
